Prestige Brings In New Management As It Consolidates CDMO Control
Prestige Biologics Gets New CEO As Prestige Biopharma Becomes Largest Shareholder
Executive Summary
Prestige Biopharma says it is acting to “consolidate group competitiveness” by taking an increased share in Prestige Biologics, at the same time as a new CEO was appointed for the CDMO.
You may also be interested in...
EMA Re-Examines Decisions On Prestige’s Trastuzumab And Synchron Studies
Following decisions by the EMA’s CHMP to deny Prestige Biopharma a marketing authorization for its trastuzumab biosimilar and to suspend the marketing authorizations of dozens of generics due to concerns over bioequivalence tests, the European regulator has confirmed it will review the opinions.
Prestige Management Fights Back Following Biosimilar Rejection
Prestige BioPharma’s top brass are looking to restore shareholder confidence following the surprise failure of their trastuzumab biosimilar before the EMA’s CHMP.
Blow For Prestige As Trastuzumab Biosimilar Rejected By EMA
Prestige Biopharma has received a setback in its attempts to win a European approval for its HD201 trastuzumab biosimilar rival to Herceptin, after the EMA’s CHMP issued a negative opinion on its parallel marketing authorization applications under the Tuznue and Hervelous labels. Prestige has 15 days in which it can ask for a re-examination of the refusals.